If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||
  Experimental DermatologyEarly View (Articles online in advance of print)Published Online: 2 Nov 2009 © 2009 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 521K) | Related Articles | Citation Tracking  Original Article
In vivo synthesis and secretion of erythropoietin by genetically modified primary human keratinocytes grafted onto immunocompromised mice Copyright © 2009 John Wiley & Sons A/S KEYWORDS erythropoietin • gene therapy • keratinocyte • selection • skin
Please cite this paper as: In vivo synthesis and secretion of erythropoietin by genetically modified primary human keratinocytes grafted onto immunocompromised mice. Experimental Dermatology 2009.
ABSTRACTBackground: The skin is an easily accessible tissue with a high blood flow facilitating the distribution of secreted peptides. These features make it a very intriguing target to serve as a biofactory releasing a systemically needed factor, such as erythropoietin (EPO). Methods: To evaluate the potential of human keratinocytes (KC) to systemically synthesize EPO, EPO-transduced KC were grafted onto immunocompromised mice and EPO secretion was followed by serum ELISA. Furthermore, we assessed if topical colchicine application would select for enriched percentages of KC expressing the multi-drug resistance (MDR) gene as a selectable gene connected to the EPO gene (measured by fluorescence-activated cell sorting (FACS)-analysis) and result in enhanced EPO production (determined by ELISA). Results: Transduced KC showed stable EPO production in vivo during a 6-month observation period, pointing to engraftment of EPO-secreting KC progenitor cells. When adding colchicines the number of EPO/MDR+ KC were significantly enriched, both in skin grafts (in vivo) and in skin equivalents (in vitro). Of note, this did not result in enhanced EPO production. Rather, while EPO secretion was substantially increased in transduced KC grown as monolayers and selected with colchicine, it was reduced by more than 50% in both colchicine-treated skin grafts and skin equivalents. Conclusion: Keratinocytes carry the potential to serve as a genetically modified biofactory synthesizing human EPO. In vivo gene selection does not allow to select for increased EPO secretion, most likely because of altered secretory activity of transduced KC in the stratified, differentiated epidermis. Thus, further studies are necessary to optimize the release of EPO by genetically modified KC. Accepted for publication17 July 2009 | 
|
| |||||||
